Yungjin Pharm. Co., Ltd. (003520.KS)
KRW 1989.0
(-2.02%)
KRW 1989.0
(-2.02%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 70.93 Billion KRW | 9.58% |
| 2022 | 64.73 Billion KRW | 11.73% |
| 2021 | 57.93 Billion KRW | -21.14% |
| 2020 | 73.46 Billion KRW | -7.91% |
| 2019 | 79.77 Billion KRW | 29.84% |
| 2018 | 61.44 Billion KRW | -10.75% |
| 2017 | 68.84 Billion KRW | -3.37% |
| 2016 | 71.24 Billion KRW | 9.91% |
| 2015 | 64.82 Billion KRW | 5.95% |
| 2014 | 61.17 Billion KRW | 7.31% |
| 2013 | 57.01 Billion KRW | 17.82% |
| 2012 | 48.38 Billion KRW | 8.2% |
| 2011 | 44.72 Billion KRW | -13.23% |
| 2010 | 51.54 Billion KRW | 18.93% |
| 2009 | 43.33 Billion KRW | -5.62% |
| 2008 | 45.92 Billion KRW | 17.05% |
| 2007 | 39.23 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 20.81 Billion KRW | 4.76% |
| 2024 Q2 | 19.5 Billion KRW | -6.32% |
| 2024 Q3 | 62.04 Billion KRW | -3.87% |
| 2023 Q4 | 19.86 Billion KRW | 9.74% |
| 2023 Q1 | 16.64 Billion KRW | -2.79% |
| 2023 Q2 | 17.23 Billion KRW | 3.57% |
| 2023 FY | 70.93 Billion KRW | 9.58% |
| 2023 Q3 | 18.1 Billion KRW | 5.06% |
| 2022 Q3 | 15.7 Billion KRW | -0.88% |
| 2022 FY | 64.73 Billion KRW | 11.73% |
| 2022 Q1 | 16.05 Billion KRW | 0.18% |
| 2022 Q2 | 15.84 Billion KRW | -1.3% |
| 2022 Q4 | 17.11 Billion KRW | 8.97% |
| 2021 Q3 | 13.8 Billion KRW | 0.53% |
| 2021 Q4 | 16.02 Billion KRW | 16.11% |
| 2021 FY | 57.93 Billion KRW | -21.14% |
| 2021 Q1 | 14.36 Billion KRW | -13.99% |
| 2021 Q2 | 13.73 Billion KRW | -4.42% |
| 2020 Q3 | 17.19 Billion KRW | -9.67% |
| 2020 Q4 | 16.7 Billion KRW | -2.83% |
| 2020 FY | 73.46 Billion KRW | -7.91% |
| 2020 Q1 | 20.53 Billion KRW | -0.66% |
| 2020 Q2 | 19.03 Billion KRW | -7.34% |
| 2019 Q3 | 20.38 Billion KRW | -1.06% |
| 2019 FY | 79.77 Billion KRW | 29.84% |
| 2019 Q1 | 18.1 Billion KRW | -6.62% |
| 2019 Q2 | 20.6 Billion KRW | 13.77% |
| 2019 Q4 | 20.67 Billion KRW | 1.41% |
| 2018 Q2 | 12.48 Billion KRW | -24.2% |
| 2018 Q1 | 16.46 Billion KRW | 4.48% |
| 2018 FY | 61.44 Billion KRW | -10.75% |
| 2018 Q4 | 19.39 Billion KRW | 48.07% |
| 2018 Q3 | 13.09 Billion KRW | 4.93% |
| 2017 Q4 | 15.76 Billion KRW | -10.22% |
| 2017 Q2 | 16.7 Billion KRW | -11.22% |
| 2017 Q1 | 18.81 Billion KRW | -0.01% |
| 2017 Q3 | 17.55 Billion KRW | 5.06% |
| 2017 FY | 68.84 Billion KRW | -3.37% |
| 2016 Q3 | 18.98 Billion KRW | 12.38% |
| 2016 Q4 | 18.82 Billion KRW | -0.84% |
| 2016 FY | 71.24 Billion KRW | 9.91% |
| 2016 Q1 | 16.55 Billion KRW | -4.57% |
| 2016 Q2 | 16.88 Billion KRW | 2.03% |
| 2015 Q2 | 15.3 Billion KRW | -0.02% |
| 2015 Q4 | 17.34 Billion KRW | 2.87% |
| 2015 Q3 | 16.86 Billion KRW | 10.18% |
| 2015 FY | 64.82 Billion KRW | 5.95% |
| 2015 Q1 | 15.3 Billion KRW | -11.69% |
| 2014 Q4 | 17.33 Billion KRW | 20.54% |
| 2014 Q3 | 14.38 Billion KRW | 2.05% |
| 2014 Q2 | 14.09 Billion KRW | -8.35% |
| 2014 Q1 | 15.37 Billion KRW | 31.41% |
| 2014 FY | 61.17 Billion KRW | 7.31% |
| 2013 FY | 57.01 Billion KRW | 17.82% |
| 2013 Q3 | 14.74 Billion KRW | -13.65% |
| 2013 Q2 | 17.07 Billion KRW | 26.64% |
| 2013 Q1 | 13.48 Billion KRW | -3.47% |
| 2013 Q4 | 11.69 Billion KRW | -20.68% |
| 2012 FY | 48.38 Billion KRW | 8.2% |
| 2012 Q4 | 13.97 Billion KRW | -3.85% |
| 2012 Q3 | 14.53 Billion KRW | 21.83% |
| 2012 Q2 | 11.92 Billion KRW | 49.82% |
| 2012 Q1 | 7.96 Billion KRW | -27.51% |
| 2011 Q3 | 9.63 Billion KRW | -18.18% |
| 2011 Q1 | 12.32 Billion KRW | -1.97% |
| 2011 Q4 | 10.98 Billion KRW | 13.96% |
| 2011 Q2 | 11.77 Billion KRW | -4.45% |
| 2011 FY | 44.72 Billion KRW | -13.23% |
| 2010 Q2 | 13.64 Billion KRW | 6.13% |
| 2010 Q1 | 12.85 Billion KRW | 3.04% |
| 2010 Q4 | 12.57 Billion KRW | 0.92% |
| 2010 Q3 | 12.46 Billion KRW | -8.7% |
| 2010 FY | 51.54 Billion KRW | 18.93% |
| 2009 FY | 43.33 Billion KRW | -5.62% |
| 2009 Q4 | 12.48 Billion KRW | 19.23% |
| 2009 Q3 | 10.46 Billion KRW | 3.93% |
| 2009 Q2 | 10.07 Billion KRW | -2.38% |
| 2009 Q1 | 10.31 Billion KRW | -15.93% |
| 2008 Q3 | 11.48 Billion KRW | 5.16% |
| 2008 Q4 | 12.27 Billion KRW | 6.86% |
| 2008 Q2 | 10.91 Billion KRW | -2.89% |
| 2008 FY | 45.92 Billion KRW | 17.05% |
| 2008 Q1 | 11.24 Billion KRW | 26.55% |
| 2007 Q2 | 5.51 Billion KRW | -57.72% |
| 2007 Q3 | 11.77 Billion KRW | 113.31% |
| 2007 Q1 | 13.05 Billion KRW | 0.0% |
| 2007 Q4 | 8.88 Billion KRW | -24.51% |
| 2007 FY | 39.23 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -52.541% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 80.517% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 64.332% |
| HANDOK Inc. | 151.36 Billion KRW | 53.134% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -5.526% |
| Yuhan Corporation | 564.5 Billion KRW | 87.433% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 77.984% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -198.728% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 91.513% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | 5.464% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 64.345% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -74.514% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 24.944% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 49.637% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -52.541% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -104.342% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | 7.653% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 688.921% |
| JW Holdings Corporation | 446.15 Billion KRW | 84.1% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 65.819% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 89.175% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 78.867% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 9.769% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | 5.714% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | 1.762% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 61.407% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -52.541% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 75.963% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 89.592% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 78.867% |
| Yuhan Corporation | 564.5 Billion KRW | 87.433% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 64.851% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 28.364% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 78.867% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 51.375% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 59.11% |
| CKD Bio Corp. | 5.01 Billion KRW | -1315.864% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 72.097% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 61.472% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 27.706% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 9.769% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 80.905% |
| Boryung Corporation | 333.26 Billion KRW | 78.714% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -41.749% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 64.345% |
| JW Lifescience Corporation | 51.32 Billion KRW | -38.216% |